Roy Buchanan
Analyst, JMP
Replay available
Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Q4 2023 earnings conference call, held 2023-11-20. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Tara Kiefer
Senior Vice President of New Product Strategy and Development
Dr. Scott Rottinghaus
Chief Medical Officer
Eric Joseph
Analyst, JPMorgan
Jay Olson
Analyst, Oppenheimer
Ed Arce
Analyst, HC Wayne Writing Company
Lisa Baco
Analyst, Evercore
Jennifer Vieira
Investor Relations
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Enanta Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.009 -- 00:00:04.390 Good afternoon, and welcome to Enanta's Pharmaceuticals Fiscal Fourth Quarter and Year-End 00:00:04.390 -- 00:00:08.151 Financial Results Conference Call. At this time, all participants are in a listen-only 00:00:08.151 -- 00:00:12.073 mode. There will be a question-and-answer session at the end of prepared remarks. 00:00:12.073 -- 00:00:14.113 Please be advised that this call is being recorded. 00:00:14.113 -- 00:00:16.254 I will now turn the conference over to your host, Ms. 00:00:16.254 -- 00:00:20.955 Jennifer Vieira, Investor Relations. Please go ahead. 00:00:22.816 -- 00:00:26.607 Thank you, Operator, and thanks to everyone for joining us this afternoon. 00:00:26.607 -- 00:00:30.609 The news release with our fiscal fourth quarter and year-end 2023 00:00:30.609 -- 00:00:36.011 financial results was issued this afternoon and is available on our website. 00:00:36.011 -- 00:00:38.873 Making formal remarks on today's call are Dr. 00:00:38.873 -- 00:00:43.795 Jay Lulli, President and Chief Executive Officer, and Paul Mellett, our Chief Financial 00:00:43.795 -- 00:00:48.217 Officer. Dr. Scott Rottinghaus, our Chief Medical Officer, and Dr. 00:00:48.217 -- 00:00:53.139 Tara Kiefer, our Senior Vice President of New Product Strategy and Development, will 00:00:53.139 -- 00:00:56.109 be available during the Q&A portion of the call. 00:00:56.109 -- 00:01:00.112 Before we begin with our formal remarks, we want to remind you that we will be making 00:01:00.112 -- 00:01:04.835 forward-looking statements, which may include our plans and expectations with respect 00:01:04.835 -- 00:01:09.519 to our research and development pipeline and financial projections, all of which involve 00:01:09.519 -- 00:01:14.682 certain assumptions and risks beyo...